Skip to main content

Table 1 Patients’ characteristics (n = 74)

From: Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling

Characteristics

 

Age (year), mean ± SD [min-max]

60 ± 14 [21;80]

Sex, n (%)

 Female

35 (47.3)%

 Male

39 (52.7)%

Age-adjusted IPI, n (%)

 0

8 (10.8)%

 1

28 (37.8)%

 2

24 (32.4)%

 3

14 (19.0)%

Deauville score at i-PET/CT, n (%)

 1

23 (31.1)%

 2

13 (17.6)%

 3

11 (14.9)%

 4

13 (17.6)%

 5

14 (18.9)%

Growth factor type (G-CSF), n (%)

 Filgrastim

52 (70.3)%

 Lenograstim

10 (13.5)%

 Pegfilgrastim

12 (16.2)%

First line of chemotherapy, n (%)

 R-CHOP

68 (91.9)%

 R-ACVBP

6 (8.1)%

Bone involvement*, n (%)

17 (23.0)%

Spleen involvement*, n (%)

8 (10.8)%

Liver involvement*, n (%)

1 (1.3)%

Baseline MATV (cc), mean ± SD

449.4 (732.0)%

  1. IPI International Prognostic Index, i-PET/CT interim PET/CT, MATV metabolic active tumour volume
  2. *Based on PET/CT analysis